

36945

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

SEARCH REQUEST FORM

Requestor's Name: Jennifer Hunt Serial Number: 09/112,041
Date: 3-4-2000 Phone: (703) 308-7542 Art Unit: 1642

Search Topic:
Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

PLEASE SEARCH A CONJUGATE OF 2 OR 3 OR MORE MONOCLONAL ANTIBODIES OF THE SAME SPECIES (homocoujugate homodimer, homotrimer), ONE OR MORE OF THE ANTIBODIES DOES NOT HAVE AN Fc REGION AND ASSERTS NO ~~AND~~ ANTI-NEOPLASTIC ACTIVITY IN UNCONJUGATED FORM, BUT THE CONJUGATE DOES HAVE ANTINEOPLASTIC ACTIVITY.

CLAIMS ARE ATTACHED

7/8/1997

Thanks,
Jennifer

Point of Contact:
Alex Wadlaw
Technical Info. Specialist
CM1 12C14 Tel: 308-4491

STAFF USE ONLY

Date completed: 3-19-01
Searcher: _____
Terminal time: _____
Elapsed time: _____
CPU time: _____
Total time: 24:15
Number of Searches: (176)
Number of Databases: (176)
R.U. 3-15-01

Search Site
☐ STIC
☒ CM-1
☐ Pre-S
Type of Search
☐ N.A. Sequence
☐ A.A. Sequence
☐ Structure
☐ Bibliographic

Vendors
☐ IG
☒ STN
☐ Dialog
☐ APS
☐ Geninfo
☐ SDC
☐ DARC/Questel
☐ Other

44
76

=> d his

(FILE 'MEDLINE' ENTERED AT 08:23:58 ON 19 MAR 2001)
 DEL HIS Y
 L1 97082 S ANTIBODIES, MONOCLONAL+NT/CT
 L2 36481 S L1/MAJ
 L3 9 S HOMOCONJUGATE?
 L4 1 S L3 AND L2
 L5 3 S L3 AND L1
 E ANTINEOPLASTIC/CT
 E E6+ALL
 E 374+ALL
 E ANTICARCINOGENIC AGENTS/CT
 E E3+ALL
 E ANTITUMOR AGENTS/CT
 L6 63391 S ANTINEOPLASTIC AGENTS/CT
 L7 0 S L6 AND L3
 L8 442 S L6 AND L2
 L9 10 S FC AND L8
 L10 205922 S SIGNAL?
 L11 17 S L8 AND L10
 L12 45513 S L6/MAJ
 L13 16 S L11 AND L12
 E SIGNAL TRANSDUCTION/CT
 E E3+ALL
 E SIGNAL TRANSDUCTION/CT
 E SIGNAL TRANSDUCTION/CT
 E E3+ALL
 L14 1268035 S C4./CT
 L15 489925 S L14 (L) TH./CT
 L16 8 S L15 AND L9
 L17 12 S L13 AND L15
 L18 19 S L16 OR L17

=> d .med 118 1-19

L18 ANSWER 1 OF 19 MEDLINE
 AN 2000424323 MEDLINE
 DN 20377422
 TI Clinical trials of antibody therapy.
 AU Glennie M J; Johnson P W
 CS Tenovus Research Laboratory, The Cancer Sciences Division, Southampton
 University School of Medicine, General Hospital, Southampton, UK SO16
 6YD.. mjj@soton.ac.uk
 SO IMMUNOLOGY TODAY, (2000 Aug) 21 (8) 403-10. Ref: 50
 Journal code: AEA. ISSN: 0167-5699.
 CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 EM 200011
 EW 20001103
 AB Much of the 25 years since Kohler and Milstein first described making

=> d his

(FILE 'HOME' ENTERED AT 08:51:25 ON 19 MAR 2001)

FILE 'WPIDS' ENTERED AT 08:51:31 ON 19 MAR 2001

L1 904 S MONOCLONAL# (L) (CONJUGAT?)
L2 254 S CD19 OR CD20 OR CD21 OR CD22 OR HER2 OR HER 2
L3 14133 S ANTINEOPLAS? OR ANTICANCER# OR ANTITUMOR# OR ANTITUMOUR#
L4 4932 S ANTI (2W) (TUMOR# OR TUMOUR# OR CANCER# OR NEOPLAS?)
L5 102 S L1 AND (L3 OR L4)
L6 12 S L1 AND L2
L7 112 S L5 OR L6
L8 7 S L7 AND SIGNAL?

=> d .wp 1-7

L8 ANSWER 1 OF 7 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
AN 2001-091571 [10] WPIDS
DNN N2001-069337 DNC C2001-027027
TI Novel inverted CCAAT box binding protein, and related nucleic acids, antibodies and specific ligands, useful for treating and preventing cancer.
DC B04 D16 S03
IN BRONNER, C; HOPFNER, R; JELTSCH, J M; LUTZ, Y; MOUSLI, M; OUDET, P; JELTSCH, J
PA (ASRE-N) ASSOC DEV RECH & GENETIQUE MOLECULAIRE; (ADER-N) ADEREGEM ASSOC DEV RECH EN GENETIQ
CYC 22
PI WO 2000078949 A1 20001228 (200110)* FR 114p
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: AU CA JP US
FR 2795414 A1 20001229 (200110)
ADT WO 2000078949 A1 WO 2000-FR1747 20000622; FR 2795414 A1 FR 1999-7935 19990622
PRAI FR 1999-7935 19990622
AB WO 200078949 A UPAB: 20010220
NOVELTY - Isolated polypeptide (I), designated ICBP90 (inverted CCAAT box binding protein) having a 793 residue amino acid sequence (S1), fully defined in the specification, is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) a polypeptide (Ia) that:
(a) has sequence (S1), or a 15, 26, or 174 residue amino acid sequence (S2, (S3), (S4), all fully defined in the specification;
(b) is a variant of (a);
(c) has at least 80, preferably 90 % homology with (a) or (b);
(d) is a fragment of at least 5 consecutive residues from (a)-(c);
or
(e) is a biologically active fragment of (a)-(c);
(2) polynucleotide (II) that:
(a) is a 2382, 45, 78, or 525 base pair sequence, all fully defined in the specification or their corresponding RNAs;
(b) is the complement of (a);
(c) has at least 80 % homology with (a) or (b);
(d) hybridizes to (a)-(c) under highly stringent conditions; or
(e) is a fragment of at least 15 nucleotides from (a)-(d);
(3) recombinant vector for cloning (II) and/or expressing (I) or